Administration of prostaglandin E1 in neonates with critical congenital cardiac defects.
Prostaglandin E1 was administered to 12 neonates and young infants in whom pulmonary or systemic blood flow was entirely or significantly dependent upon persistent patency of the ductus arteriosus. Nine neonates responded favorably to PGE1 infusion; their mean age was 2.8 days. Three infants who failed to respond were 10 days, 14 days, and 9 weeks of age, respectively. Six neonates with right ventricular outflow obstruction had a mean increase in arterial PO2 of 136% following administration of PGE1. In three patients in whom systemic flow was ductus dependent, PGE1 infusion was followed by improvement in arterial blood pressure, peripheral perfusion, and urine output. Complications included pyrexia, vasodilatation, and myoclonic jerks (or focal seizures). Three side effects were easily reversible by decreasing the infusion rate or altering the site of administration. PGE1 is a highly effective agent in stabilizing critically ill neonates with ductus dependent congenital cardiac lesions.
D001794:Blood Pressure; D003490:Cyanosis / Q000209:etiology; D004374:Ductus Arteriosus, Patent / Q000503:physiopathology; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D010100:Oxygen / Q000097:blood; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*
D011458:Prostaglandins E; D010100:Oxygen